혁신 신약 CRO 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of innovative drug CRO Market

The global innovative drug CRO market size was valued at USD 61.23 billion in 2025 and is projected to grow from USD 67.19 billion in 2026 to USD 121.11 billion by 2034, registering a CAGR of 7.6% during the forecast period. North America dominated the market with a 35.33% market share in 2025, valued at USD 21.63 billion. The market covers outsourced research and development services for innovative medicines, including new molecular entities, biologics, cell and gene therapies, RNA-based therapeutics, radiopharmaceuticals, and other differentiated drug candidates.

The market encompasses drug discovery, preclinical development, clinical trials, laboratory and bioanalytical services, data management, medical writing, regulatory affairs, pharmacovigilance, and real-world evidence. Increasing drug-development complexity, expanding biotechnology pipelines, rising clinical-trial costs, and growing demand for specialized scientific expertise are supporting Market Growth.

Market Trends

AI Integration and Digitally Connected Clinical Trials

Artificial intelligence is becoming increasingly important across drug discovery and clinical development. CROs are using AI for target identification, molecule optimization, protocol development, site selection, patient recruitment, data analysis, and pharmacovigilance. In June 2025, IQVIA introduced AI agents developed using NVIDIA technology to improve life-sciences workflows and accelerate insights. Increasing adoption of digital clinical platforms is expected to strengthen operational efficiency and support the Market Outlook through 2034.

Market Dynamics

Driver - Increasing Complexity of Innovative Drug Development

Innovative therapies require specialized capabilities in biomarkers, genomic testing, immunogenicity, advanced trial design, regulatory strategy, and multinational patient recruitment. Cell and gene therapies, bispecific antibodies, antibody-drug conjugates, and RNA therapeutics also involve specialized development requirements. Consequently, pharmaceutical and biotechnology companies increasingly outsource activities to CROs with global clinical networks, specialized laboratories, regulatory expertise, and advanced data capabilities.

Restraint - High Development Costs and Clinical-Trial Failure Risks

Innovative drug development requires significant investment in clinical research, specialized laboratory testing, multinational trial networks, regulatory documentation, and manufacturing coordination. Clinical delays, patient-recruitment difficulties, unsuccessful endpoints, and safety-related discontinuations can cause sponsors to postpone or cancel outsourcing programs. Budget pressure and vendor consolidation can also affect CRO profitability and contract volumes.

Market Opportunity - Expansion of Emerging Biopharmaceutical Pipelines

Small and mid-sized biotechnology companies represent an important Market Opportunity because many have innovative pipelines but limited internal clinical-development infrastructure. CROs can address this demand through integrated discovery-to-clinical services, dedicated biotech teams, flexible development packages, and strategic outsourcing models.

Market Challenge - Regulatory Complexity and Data Quality

CROs must comply with changing regulatory requirements across multiple jurisdictions while maintaining consistent clinical data quality. Advanced therapies require specialized trial designs, long-term follow-up, sophisticated bioanalytical testing, and extensive safety monitoring. Growing demand for real-time data visibility and inspection-ready documentation further increases the need for digital infrastructure and specialized personnel.

Segmentation Analysis

By Service Type

The market is segmented into drug discovery, preclinical development, clinical development, laboratory and bioanalytical services, data management and medical writing, regulatory affairs, safety and pharmacovigilance, and real-world evidence and late-phase services. Clinical development services dominated in 2025, supported by the high operational and financial requirements of Phase I-III clinical trials. Drug discovery services are projected to grow at a CAGR of 8.7%.

By Development Stage

The market includes drug discovery, preclinical development, Phase I, Phase II, Phase III, and post-approval/Phase IV. Phase III held a 29.4% market share in 2025, driven by large patient populations, multinational sites, extensive monitoring, regulatory coordination, and complex statistical requirements. Drug discovery is projected to expand at a CAGR of 8.7%.

By Drug Modality

Small-molecule drugs, biologics, cell therapies, gene therapies, RNA-based therapeutics, and others constitute the major segments. Small-molecule drugs held a 40.9% share in 2025, supported by extensive use across oncology, neurology, cardiovascular, metabolic, infectious, and immunological applications. RNA-based therapeutics are expected to grow at a CAGR of 11.9%.

By Therapeutic Area

The market covers oncology, neurology and CNS disorders, cardiovascular diseases, metabolic and endocrine disorders, immunology and autoimmune diseases, infectious diseases, respiratory diseases, and others. Oncology held a 34.4% share in 2025, supported by extensive cancer pipelines, biomarker testing, adaptive trials, biologics, ADCs, cell therapies, and radiopharmaceutical development. Immunology and autoimmune diseases are projected to grow at a CAGR of 8.6%.

By Outsourcing Model

Full-service outsourcing, functional service provider outsourcing, and hybrid/strategic outsourcing are covered. Full-service outsourcing accounted for 55.2% of the market in 2025, as sponsors increasingly seek integrated clinical, data, regulatory, safety, and laboratory support. Hybrid/strategic outsourcing is projected to grow at a CAGR of 9.0%.

By Sponsor Type

Large biopharmaceutical companies, small and mid-sized biopharmaceutical companies, academic and research institutions, and others constitute the segments. Large biopharmaceutical companies held a 48.5% share in 2025, supported by extensive pipelines and multinational clinical programs. Small and mid-sized biopharmaceutical companies are projected to grow at a CAGR of 8.9%.

Regional Outlook

North America

North America generated a market value of USD 21.63 billion in 2025, increasing from USD 19.74 billion in 2024. The region's position is supported by high pharmaceutical and biotechnology R&D spending, advanced clinical infrastructure, large biopharmaceutical pipelines, and strong adoption of innovative therapies.

U.S.

The U.S. represents the largest national market within North America. Its market is supported by extensive clinical-trial infrastructure, biotechnology investment, pharmaceutical R&D, and demand for specialized CRO services.

Europe

Europe is projected to reach USD 17.94 billion in 2026, with a growth rate of 6.5%. The U.K. market is estimated at USD 3.59 billion in 2026, while Germany is projected to reach USD 3.95 billion.

Asia Pacific

Asia Pacific is projected to reach USD 20.50 billion in 2026, supported by expanding clinical-trial activity, large patient populations, competitive development costs, and improving pharmaceutical capabilities. China is estimated at USD 7.02 billion, Japan at USD 4.01 billion, and India at USD 3.14 billion in 2026.

Latin America and Middle East & Africa

Latin America is projected to reach USD 3.08 billion in 2026, while the GCC market is expected to reach USD 0.79 billion. South Africa is projected at approximately USD 0.41 billion in 2026. Growth is supported by expanding clinical research and pharmaceutical development, although infrastructure and regulatory differences remain relevant factors.

Competitive Landscape

The competitive landscape includes IQVIA Biotech, ICON plc, Thermo Fisher Scientific, Parexel International, WuXi Chemistry, Charles River Laboratories, Hangzhou Tigermed, Syngene International, CMIC Holdings, and Avance Clinical. Leading companies are expanding integrated CRO capabilities, AI-enabled clinical platforms, laboratory infrastructure, oncology services, and advanced-therapy expertise.

Key Industry Developments

In May 2026, Parexel launched ParexelAI, an AI-enabled clinical development suite supporting trial execution, site selection, medical writing, and pharmacovigilance workflows. In February 2025, Charles River Laboratories expanded its collaboration with Deciphex for AI-enabled toxicologic pathology. In January 2025, Charles River partnered with Lundbeck to use the AI-powered Logica platform for small-molecule discovery. In October 2024, Thermo Fisher Scientific introduced Accelerator Drug Development, combining CRO and CDMO capabilities. In September 2024, ICON acquired KCR to strengthen its clinical research capabilities.

Report Coverage

The Innovative Drug CRO Market Report provides comprehensive Market Research Report coverage of market size, market value, segmentation, regional performance, Market Trends, Market Analysis, Industry Analysis, Market Forecast, competitive developments, technological advancements, partnerships, acquisitions, and investment activity. The Industry Report evaluates service type, development stage, drug modality, therapeutic area, outsourcing model, and sponsor type while examining key Market Opportunities and challenges influencing the Market Outlook through 2034.

Conclusion

The global innovative drug CRO market is expanding as pharmaceutical and biotechnology companies increasingly rely on specialized external partners to manage complex drug-development programs. The market size is expected to increase from USD 61.23 billion in 2025 to USD 67.19 billion in 2026 and USD 121.11 billion by 2034. Clinical development services, Phase III programs, small-molecule drugs, oncology, full-service outsourcing, and large biopharmaceutical sponsors remain important components of the market. At the same time, AI-enabled development, advanced therapies, RNA-based therapeutics, and growing biotechnology pipelines are creating new Market Opportunities. Regulatory complexity, development costs, clinical risks, and skilled-workforce requirements will continue to shape the market through 2034.

Segmentation By Service Type, Development Stage, Drug Modality, Therapeutic Area, Outsourcing Model, Sponsor Type, and Region

By Service Type

• Drug Discovery Services
  • Target Identification & Validation
  • Assay Development & High-Throughput Screening
  • Lead Optimization
  • Others
• Preclinical Development Services
  • In-vitro Testing
  • Toxicology & Safety Assessment
  • Others
• Clinical Development Services
  • Site Identification, Selection & Management
  • Clinical Monitoring
  • Project & Vendor Management
  • Others
• Laboratory & Bioanalytical Services
• Data Management & Medical Writing
• Regulatory Affairs Services
• Safety & Pharmacovigilance Services
• Real-World Evidence & Late-Phase Services

By Development Stage

• Drug Discovery
• Preclinical Development
• Phase I
• Phase II
• Phase III
• Post-Approval / Phase IV

By Drug Modality

• Small-Molecule Drugs
• Biologics
• Cell Therapies
  • Autologous Cell Therapies
  • Allogeneic Cell Therapies
  • Other Cell Therapies
• Gene Therapies
  • In-vivo Gene Therapies
  • Ex-vivo Gene Therapies
• RNA-Based Therapeutics
• Others

By Therapeutic Area

• Oncology
• Neurology & CNS Disorders
• Cardiovascular Diseases
• Metabolic & Endocrine Disorders
• Immunology & Autoimmune Diseases
• Infectious Diseases
• Respiratory Diseases
• Others

By Outsourcing Model

• Full-Service Outsourcing
• Functional Service Provider Outsourcing
• Hybrid / Strategic Outsourcing

By Sponsor Type

• Large Biopharmaceutical Companies
• Small & Mid-Sized Biopharmaceutical Companies
• Academic & Research Institutions
• Others

By Region

• North America (By Service Type, Development Stage, Drug Modality, Therapeutic Area, Outsourcing Model, Sponsor Type, and Country)
  • U.S.
• By Service Type
  • Canada
• By Service Type
• Europe (By Service Type, Development Stage, Drug Modality, Therapeutic Area, Outsourcing Model, Sponsor Type, and Country/Sub-region)
  • Germany
• By Service Type
  • U.K.
• By Service Type
  • France
• By Service Type
  • Spain
• By Service Type
  • Italy
• By Service Type
  • Scandinavia
• By Service Type
  • Rest of Europe
• By Service Type
• Asia Pacific (By Service Type, Development Stage, Drug Modality, Therapeutic Area, Outsourcing Model, Sponsor Type, and Country/Sub-region)
  • China
• By Service Type
  • Japan
• By Service Type
  • India
• By Service Type
  • Australia
• By Service Type
  • Southeast Asia
• By Service Type
  • Rest of Asia Pacific
• By Service Type
• Latin America (By Service Type, Development Stage, Drug Modality, Therapeutic Area, Outsourcing Model, Sponsor Type, and Country/Sub-region)
  • Brazil
• By Service Type
  • Mexico
• By Service Type
  • Rest of Latin America
• By Service Type
• Middle East & Africa (By Service Type, Development Stage, Drug Modality, Therapeutic Area, Outsourcing Model, Sponsor Type, and Country/Sub-region)
  • GCC
• By Service Type
  • South Africa
• By Service Type
  • Rest of Middle East & Africa
• By Service Type

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Challenges
• 3.5. Market Trends

4. Key Insights

• 4.1. Investment by Key Players, Key Countries, 2025
• 4.2. Technological Advancements in Innovative Drug CRO
• 4.3. Key Industry Developments - Mergers, Acquisitions & Partnerships

5. Global Innovative Drug CRO Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Service Type
  • 5.1.1. Drug Discovery Services
    • 5.1.1.1. Target Identification & Validation
    • 5.1.1.2. Assay Development & High-Throughput Screening
    • 5.1.1.3. Lead Optimization
    • 5.1.1.4. Others
  • 5.1.2. Preclinical Development Services
    • 5.1.2.1. In-vitro Testing
    • 5.1.2.2. Toxicology & Safety Assessment
    • 5.1.2.3. Others
  • 5.1.3. Clinical Development Services
    • 5.1.3.1. Site Identification, Selection & Management
    • 5.1.3.2. Clinical Monitoring
    • 5.1.3.3. Project & Vendor Management
    • 5.1.3.4. Others
  • 5.1.4. Laboratory & Bioanalytical Services
  • 5.1.5. Data Management & Medical Writing
  • 5.1.6. Regulatory Affairs Services
  • 5.1.7. Safety & Pharmacovigilance Services
  • 5.1.8. Real-World Evidence & Late-Phase Services
• 5.2. Market Analysis, Insights and Forecast - By Development Stage
  • 5.2.1. Drug Discovery
  • 5.2.2. Preclinical Development
  • 5.2.3. Phase I
  • 5.2.4. Phase II
  • 5.2.5. Phase III
  • 5.2.6. Post-Approval / Phase IV
• 5.3. Market Analysis, Insights and Forecast - By Drug Modality
  • 5.3.1. Small-Molecule Drugs
  • 5.3.2. Biologics
  • 5.3.3. Cell Therapies
    • 5.3.3.1. Autologous Cell Therapies
    • 5.3.3.2. Allogeneic Cell Therapies
    • 5.3.3.3. Other Cell Therapies
  • 5.3.4. Gene Therapies
    • 5.3.4.1. In-vivo Gene Therapies
    • 5.3.4.2. Ex-vivo Gene Therapies
  • 5.3.5. RNA-Based Therapeutics
  • 5.3.6. Others
• 5.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 5.4.1. Oncology
  • 5.4.2. Neurology & CNS Disorders
  • 5.4.3. Cardiovascular Diseases
  • 5.4.4. Metabolic & Endocrine Disorders
  • 5.4.5. Immunology & Autoimmune Diseases
  • 5.4.6. Infectious Diseases
  • 5.4.7. Respiratory Diseases
  • 5.4.8. Others
• 5.5. Market Analysis, Insights and Forecast - By Outsourcing Model
  • 5.5.1. Full-Service Outsourcing
  • 5.5.2. Functional Service Provider Outsourcing
  • 5.5.3. Hybrid / Strategic Outsourcing
• 5.6. Market Analysis, Insights and Forecast - By Sponsor Type
  • 5.6.1. Large Biopharmaceutical Companies
  • 5.6.2. Small & Mid-Sized Biopharmaceutical Companies
  • 5.6.3. Academic & Research Institutions
  • 5.6.4. Others
• 5.7. Market Analysis, Insights and Forecast - By Region
  • 5.7.1. North America
  • 5.7.2. Europe
  • 5.7.3. Asia Pacific
  • 5.7.4. Latin America
  • 5.7.5. Middle East & Africa

6. North America Innovative Drug CRO Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Service Type
  • 6.1.1. Drug Discovery Services
    • 6.1.1.1. Target Identification & Validation
    • 6.1.1.2. Assay Development & High-Throughput Screening
    • 6.1.1.3. Lead Optimization
    • 6.1.1.4. Others
  • 6.1.2. Preclinical Development Services
    • 6.1.2.1. In-vitro Testing
    • 6.1.2.2. Toxicology & Safety Assessment
    • 6.1.2.3. Others
  • 6.1.3. Clinical Development Services
    • 6.1.3.1. Site Identification, Selection & Management
    • 6.1.3.2. Clinical Monitoring
    • 6.1.3.3. Project & Vendor Management
    • 6.1.3.4. Others
  • 6.1.4. Laboratory & Bioanalytical Services
  • 6.1.5. Data Management & Medical Writing
  • 6.1.6. Regulatory Affairs Services
  • 6.1.7. Safety & Pharmacovigilance Services
  • 6.1.8. Real-World Evidence & Late-Phase Services
• 6.2. Market Analysis, Insights and Forecast - By Development Stage
  • 6.2.1. Drug Discovery
  • 6.2.2. Preclinical Development
  • 6.2.3. Phase I
  • 6.2.4. Phase II
  • 6.2.5. Phase III
  • 6.2.6. Post-Approval / Phase IV
• 6.3. Market Analysis, Insights and Forecast - By Drug Modality
  • 6.3.1. Small-Molecule Drugs
  • 6.3.2. Biologics
  • 6.3.3. Cell Therapies
    • 6.3.3.1. Autologous Cell Therapies
    • 6.3.3.2. Allogeneic Cell Therapies
    • 6.3.3.3. Other Cell Therapies
  • 6.3.4. Gene Therapies
    • 6.3.4.1. In-vivo Gene Therapies
    • 6.3.4.2. Ex-vivo Gene Therapies
  • 6.3.5. RNA-Based Therapeutics
  • 6.3.6. Others
• 6.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 6.4.1. Oncology
  • 6.4.2. Neurology & CNS Disorders
  • 6.4.3. Cardiovascular Diseases
  • 6.4.4. Metabolic & Endocrine Disorders
  • 6.4.5. Immunology & Autoimmune Diseases
  • 6.4.6. Infectious Diseases
  • 6.4.7. Respiratory Diseases
  • 6.4.8. Others
• 6.5. Market Analysis, Insights and Forecast - By Outsourcing Model
  • 6.5.1. Full-Service Outsourcing
  • 6.5.2. Functional Service Provider Outsourcing
  • 6.5.3. Hybrid / Strategic Outsourcing
• 6.6. Market Analysis, Insights and Forecast - By Sponsor Type
  • 6.6.1. Large Biopharmaceutical Companies
  • 6.6.2. Small & Mid-Sized Biopharmaceutical Companies
  • 6.6.3. Academic & Research Institutions
  • 6.6.4. Others
• 6.7. Market Analysis, Insights and Forecast - By Country
  • 6.7.1. U.S.
    • 6.7.1.1. By Service Type
  • 6.7.2. Canada
    • 6.7.2.1. By Service Type

7. Europe Innovative Drug CRO Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Service Type
  • 7.1.1. Drug Discovery Services
    • 7.1.1.1. Target Identification & Validation
    • 7.1.1.2. Assay Development & High-Throughput Screening
    • 7.1.1.3. Lead Optimization
    • 7.1.1.4. Others
  • 7.1.2. Preclinical Development Services
    • 7.1.2.1. In-vitro Testing
    • 7.1.2.2. Toxicology & Safety Assessment
    • 7.1.2.3. Others
  • 7.1.3. Clinical Development Services
    • 7.1.3.1. Site Identification, Selection & Management
    • 7.1.3.2. Clinical Monitoring
    • 7.1.3.3. Project & Vendor Management
    • 7.1.3.4. Others
  • 7.1.4. Laboratory & Bioanalytical Services
  • 7.1.5. Data Management & Medical Writing
  • 7.1.6. Regulatory Affairs Services
  • 7.1.7. Safety & Pharmacovigilance Services
  • 7.1.8. Real-World Evidence & Late-Phase Services
• 7.2. Market Analysis, Insights and Forecast - By Development Stage
  • 7.2.1. Drug Discovery
  • 7.2.2. Preclinical Development
  • 7.2.3. Phase I
  • 7.2.4. Phase II
  • 7.2.5. Phase III
  • 7.2.6. Post-Approval / Phase IV
• 7.3. Market Analysis, Insights and Forecast - By Drug Modality
  • 7.3.1. Small-Molecule Drugs
  • 7.3.2. Biologics
  • 7.3.3. Cell Therapies
    • 7.3.3.1. Autologous Cell Therapies
    • 7.3.3.2. Allogeneic Cell Therapies
    • 7.3.3.3. Other Cell Therapies
  • 7.3.4. Gene Therapies
    • 7.3.4.1. In-vivo Gene Therapies
    • 7.3.4.2. Ex-vivo Gene Therapies
  • 7.3.5. RNA-Based Therapeutics
  • 7.3.6. Others
• 7.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 7.4.1. Oncology
  • 7.4.2. Neurology & CNS Disorders
  • 7.4.3. Cardiovascular Diseases
  • 7.4.4. Metabolic & Endocrine Disorders
  • 7.4.5. Immunology & Autoimmune Diseases
  • 7.4.6. Infectious Diseases
  • 7.4.7. Respiratory Diseases
  • 7.4.8. Others
• 7.5. Market Analysis, Insights and Forecast - By Outsourcing Model
  • 7.5.1. Full-Service Outsourcing
  • 7.5.2. Functional Service Provider Outsourcing
  • 7.5.3. Hybrid / Strategic Outsourcing
• 7.6. Market Analysis, Insights and Forecast - By Sponsor Type
  • 7.6.1. Large Biopharmaceutical Companies
  • 7.6.2. Small & Mid-Sized Biopharmaceutical Companies
  • 7.6.3. Academic & Research Institutions
  • 7.6.4. Others
• 7.7. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.7.1. U.K.
    • 7.7.1.1. By Service Type
  • 7.7.2. Germany
    • 7.7.2.1. By Service Type
  • 7.7.3. France
    • 7.7.3.1. By Service Type
  • 7.7.4. Spain
    • 7.7.4.1. By Service Type
  • 7.7.5. Italy
    • 7.7.5.1. By Service Type
  • 7.7.6. Scandinavia
    • 7.7.6.1. By Service Type
  • 7.7.7. Rest of Europe
    • 7.7.7.1. By Service Type

8. Asia Pacific Innovative Drug CRO Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Service Type
  • 8.1.1. Drug Discovery Services
    • 8.1.1.1. Target Identification & Validation
    • 8.1.1.2. Assay Development & High-Throughput Screening
    • 8.1.1.3. Lead Optimization
    • 8.1.1.4. Others
  • 8.1.2. Preclinical Development Services
    • 8.1.2.1. In-vitro Testing
    • 8.1.2.2. Toxicology & Safety Assessment
    • 8.1.2.3. Others
  • 8.1.3. Clinical Development Services
    • 8.1.3.1. Site Identification, Selection & Management
    • 8.1.3.2. Clinical Monitoring
    • 8.1.3.3. Project & Vendor Management
    • 8.1.3.4. Others
  • 8.1.4. Laboratory & Bioanalytical Services
  • 8.1.5. Data Management & Medical Writing
  • 8.1.6. Regulatory Affairs Services
  • 8.1.7. Safety & Pharmacovigilance Services
  • 8.1.8. Real-World Evidence & Late-Phase Services
• 8.2. Market Analysis, Insights and Forecast - By Development Stage
  • 8.2.1. Drug Discovery
  • 8.2.2. Preclinical Development
  • 8.2.3. Phase I
  • 8.2.4. Phase II
  • 8.2.5. Phase III
  • 8.2.6. Post-Approval / Phase IV
• 8.3. Market Analysis, Insights and Forecast - By Drug Modality
  • 8.3.1. Small-Molecule Drugs
  • 8.3.2. Biologics
  • 8.3.3. Cell Therapies
    • 8.3.3.1. Autologous Cell Therapies
    • 8.3.3.2. Allogeneic Cell Therapies
    • 8.3.3.3. Other Cell Therapies
  • 8.3.4. Gene Therapies
    • 8.3.4.1. In-vivo Gene Therapies
    • 8.3.4.2. Ex-vivo Gene Therapies
  • 8.3.5. RNA-Based Therapeutics
  • 8.3.6. Others
• 8.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 8.4.1. Oncology
  • 8.4.2. Neurology & CNS Disorders
  • 8.4.3. Cardiovascular Diseases
  • 8.4.4. Metabolic & Endocrine Disorders
  • 8.4.5. Immunology & Autoimmune Diseases
  • 8.4.6. Infectious Diseases
  • 8.4.7. Respiratory Diseases
  • 8.4.8. Others
• 8.5. Market Analysis, Insights and Forecast - By Outsourcing Model
  • 8.5.1. Full-Service Outsourcing
  • 8.5.2. Functional Service Provider Outsourcing
  • 8.5.3. Hybrid / Strategic Outsourcing
• 8.6. Market Analysis, Insights and Forecast - By Sponsor Type
  • 8.6.1. Large Biopharmaceutical Companies
  • 8.6.2. Small & Mid-Sized Biopharmaceutical Companies
  • 8.6.3. Academic & Research Institutions
  • 8.6.4. Others
• 8.7. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.7.1. Japan
    • 8.7.1.1. By Service Type
  • 8.7.2. Australia
    • 8.7.2.1. By Service Type
  • 8.7.3. China
    • 8.7.3.1. By Service Type
  • 8.7.4. India
    • 8.7.4.1. By Service Type
  • 8.7.5. Southeast Asia
    • 8.7.5.1. By Service Type
  • 8.7.6. Rest of Asia Pacific
    • 8.7.6.1. By Service Type

9. Latin America Innovative Drug CRO Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Service Type
  • 9.1.1. Drug Discovery Services
    • 9.1.1.1. Target Identification & Validation
    • 9.1.1.2. Assay Development & High-Throughput Screening
    • 9.1.1.3. Lead Optimization
    • 9.1.1.4. Others
  • 9.1.2. Preclinical Development Services
    • 9.1.2.1. In-vitro Testing
    • 9.1.2.2. Toxicology & Safety Assessment
    • 9.1.2.3. Others
  • 9.1.3. Clinical Development Services
    • 9.1.3.1. Site Identification, Selection & Management
    • 9.1.3.2. Clinical Monitoring
    • 9.1.3.3. Project & Vendor Management
    • 9.1.3.4. Others
  • 9.1.4. Laboratory & Bioanalytical Services
  • 9.1.5. Data Management & Medical Writing
  • 9.1.6. Regulatory Affairs Services
  • 9.1.7. Safety & Pharmacovigilance Services
  • 9.1.8. Real-World Evidence & Late-Phase Services
• 9.2. Market Analysis, Insights and Forecast - By Development Stage
  • 9.2.1. Drug Discovery
  • 9.2.2. Preclinical Development
  • 9.2.3. Phase I
  • 9.2.4. Phase II
  • 9.2.5. Phase III
  • 9.2.6. Post-Approval / Phase IV
• 9.3. Market Analysis, Insights and Forecast - By Drug Modality
  • 9.3.1. Small-Molecule Drugs
  • 9.3.2. Biologics
  • 9.3.3. Cell Therapies
    • 9.3.3.1. Autologous Cell Therapies
    • 9.3.3.2. Allogeneic Cell Therapies
    • 9.3.3.3. Other Cell Therapies
  • 9.3.4. Gene Therapies
    • 9.3.4.1. In-vivo Gene Therapies
    • 9.3.4.2. Ex-vivo Gene Therapies
  • 9.3.5. RNA-Based Therapeutics
  • 9.3.6. Others
• 9.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 9.4.1. Oncology
  • 9.4.2. Neurology & CNS Disorders
  • 9.4.3. Cardiovascular Diseases
  • 9.4.4. Metabolic & Endocrine Disorders
  • 9.4.5. Immunology & Autoimmune Diseases
  • 9.4.6. Infectious Diseases
  • 9.4.7. Respiratory Diseases
  • 9.4.8. Others
• 9.5. Market Analysis, Insights and Forecast - By Outsourcing Model
  • 9.5.1. Full-Service Outsourcing
  • 9.5.2. Functional Service Provider Outsourcing
  • 9.5.3. Hybrid / Strategic Outsourcing
• 9.6. Market Analysis, Insights and Forecast - By Sponsor Type
  • 9.6.1. Large Biopharmaceutical Companies
  • 9.6.2. Small & Mid-Sized Biopharmaceutical Companies
  • 9.6.3. Academic & Research Institutions
  • 9.6.4. Others
• 9.7. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.7.1. Brazil
    • 9.7.1.1. By Service Type
  • 9.7.2. Mexico
    • 9.7.2.1. By Service Type
  • 9.7.3. Rest of Latin America
    • 9.7.3.1. By Service Type

10. Middle East & Africa Innovative Drug CRO Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Service Type
  • 10.1.1. Drug Discovery Services
    • 10.1.1.1. Target Identification & Validation
    • 10.1.1.2. Assay Development & High-Throughput Screening
    • 10.1.1.3. Lead Optimization
    • 10.1.1.4. Others
  • 10.1.2. Preclinical Development Services
    • 10.1.2.1. In-vitro Testing
    • 10.1.2.2. Toxicology & Safety Assessment
    • 10.1.2.3. Others
  • 10.1.3. Clinical Development Services
    • 10.1.3.1. Site Identification, Selection & Management
    • 10.1.3.2. Clinical Monitoring
    • 10.1.3.3. Project & Vendor Management
    • 10.1.3.4. Others
  • 10.1.4. Laboratory & Bioanalytical Services
  • 10.1.5. Data Management & Medical Writing
  • 10.1.6. Regulatory Affairs Services
  • 10.1.7. Safety & Pharmacovigilance Services
  • 10.1.8. Real-World Evidence & Late-Phase Services
• 10.2. Market Analysis, Insights and Forecast - By Development Stage
  • 10.2.1. Drug Discovery
  • 10.2.2. Preclinical Development
  • 10.2.3. Phase I
  • 10.2.4. Phase II
  • 10.2.5. Phase III
  • 10.2.6. Post-Approval / Phase IV
• 10.3. Market Analysis, Insights and Forecast - By Drug Modality
  • 10.3.1. Small-Molecule Drugs
  • 10.3.2. Biologics
  • 10.3.3. Cell Therapies
    • 10.3.3.1. Autologous Cell Therapies
    • 10.3.3.2. Allogeneic Cell Therapies
    • 10.3.3.3. Other Cell Therapies
  • 10.3.4. Gene Therapies
    • 10.3.4.1. In-vivo Gene Therapies
    • 10.3.4.2. Ex-vivo Gene Therapies
  • 10.3.5. RNA-Based Therapeutics
  • 10.3.6. Others
• 10.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 10.4.1. Oncology
  • 10.4.2. Neurology & CNS Disorders
  • 10.4.3. Cardiovascular Diseases
  • 10.4.4. Metabolic & Endocrine Disorders
  • 10.4.5. Immunology & Autoimmune Diseases
  • 10.4.6. Infectious Diseases
  • 10.4.7. Respiratory Diseases
  • 10.4.8. Others
• 10.5. Market Analysis, Insights and Forecast - By Outsourcing Model
  • 10.5.1. Full-Service Outsourcing
  • 10.5.2. Functional Service Provider Outsourcing
  • 10.5.3. Hybrid / Strategic Outsourcing
• 10.6. Market Analysis, Insights and Forecast - By Sponsor Type
  • 10.6.1. Large Biopharmaceutical Companies
  • 10.6.2. Small & Mid-Sized Biopharmaceutical Companies
  • 10.6.3. Academic & Research Institutions
  • 10.6.4. Others
• 10.7. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.7.1. South Africa
    • 10.7.1.1. By Service Type
  • 10.7.2. GCC
    • 10.7.2.1. By Service Type
  • 10.7.3. Rest of Middle East & Africa
    • 10.7.3.1. By Service Type

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. IQVIA Biotech
  • 11.2.2. ICON plc
  • 11.2.3. Thermo Fisher Scientific Inc.
  • 11.2.4. Parexel International Corporation
  • 11.2.5. WuXi Chemistry
  • 11.2.6. Charles River Laboratories
  • 11.2.7. Hangzhou Tigermed Consulting Co., Ltd.
  • 11.2.8. Syngene International Limited
  • 11.2.9. CMIC Holdings Co., Ltd.
  • 11.2.10. Avance Clinical Pty Ltd.